Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT); Advanced Hematologic Malignancies; Acute Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders Interventions: Drug: Purified regulatory T-cells (Treg) plus CD34+ HSPC; Drug: Fludarabine; Drug: Melphalan; Device: CliniMACS CD34 Reagent System; Drug: Tacrolimus; Drug: Cyclophosphamide; Drug: Plerixafor; Drug: Filgrastim granulocyte colony-stimulating factor (G-CSF) or equival ent Sponsors: Stanford University; Orca Biosystems, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2021 Category: Research Source Type: clinical trials
